📰 Nasdaq Prtk News
Page 3 - Nasdaq Prtk News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Prtk. Real-time updates on events, politics, business and more.
May 13, 2023
Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) had its target price trimmed by BTIG Research from $24.00 to $5.00 in a research report sent to investors on Tuesday morning, The Fly reports. A number of other analysts have also issued reports on PRTK. HC Wainwright lowered their price target on Paratek Pharmaceuticals from $20.00 to $10.00 […]
May 12, 2023
Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) had its target price lowered by BTIG Research from $24.00 to $5.00 in a research note published on Tuesday morning, The Fly reports. PRTK has been the topic of a number of other research reports. HC Wainwright lowered their target price on Paratek Pharmaceuticals from $20.00 to $10.00 in […]
May 12, 2023
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) – HC Wainwright raised their Q2 2023 earnings per share estimates for Paratek Pharmaceuticals in a report issued on Wednesday, May 10th. HC Wainwright analyst E. Arce now anticipates that the specialty pharmaceutical company will earn ($0.30) per share for the quarter, up from their previous forecast of […]
April 13, 2023
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating)’s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.25 and traded as high as $2.63. Paratek Pharmaceuticals shares last traded at $2.57, with a volume of 367,602 shares. Wall Street Analyst Weigh In PRTK has […]
April 1, 2023
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) major shareholder James D. Dondero purchased 105,137 shares of the company’s stock in a transaction on Monday, March 20th. The shares were purchased at an average price of $1.40 per share, for a total transaction of $147,191.80. Following the purchase, the insider now owns 2,239,770 shares in the […]
March 30, 2023
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) major shareholder James D. Dondero purchased 234,863 shares of the business’s stock in a transaction that occurred on Friday, March 17th. The shares were purchased at an average cost of $1.50 per share, with a total value of $352,294.50. Following the completion of the acquisition, the insider now […]
March 30, 2023
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) major shareholder James D. Dondero purchased 105,137 shares of the firm’s stock in a transaction on Monday, March 20th. The stock was bought at an average price of $1.40 per share, for a total transaction of $147,191.80. Following the completion of the transaction, the insider now directly owns […]
March 30, 2023
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) major shareholder James D. Dondero bought 106,000 shares of the business’s stock in a transaction on Wednesday, March 22nd. The shares were acquired at an average cost of $1.77 per share, for a total transaction of $187,620.00. Following the purchase, the insider now directly owns 2,056,000 shares in […]
March 24, 2023
Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) had its target price lowered by HC Wainwright from $20.00 to $10.00 in a research report sent to investors on Monday morning, The Fly reports. HC Wainwright also issued estimates for Paratek Pharmaceuticals’ Q1 2023 earnings at ($0.27) EPS, Q2 2023 earnings at ($0.24) EPS, Q3 2023 earnings at […]
March 24, 2023
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) – Equities researchers at HC Wainwright lowered their Q1 2023 earnings estimates for Paratek Pharmaceuticals in a report issued on Monday, March 20th. HC Wainwright analyst E. Arce now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.27) for the quarter, down from their […]